Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
24 hedge funds and large institutions have $7.11M invested in Cellular Biomedicine Group, Inc. in 2017 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 18 closing their positions.
29% less funds holding
Funds holding: 34 → 24 (-10)
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
57% less capital invested
Capital invested by funds: $16.4M → $7.11M (-$9.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.36M |
| 2 |
Goldman Sachs
New York
|
+$544K |
| 3 |
ECM
Element Capital Management
New York
|
+$408K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$392K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$322K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.51M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$903K |
| 4 |
Bank of New York Mellon
New York
|
-$475K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$389K |
CBMG Hedge Fund Activity: Q2 2017 in Review
24 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q2 2017, worth a combined $7.11M — down 57% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CBMG and 8 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Millennium Management, adding an estimated $1.36M. The largest seller was BlackRock, cutting an estimated $4.5M.
- 24 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q2 2017, down from 34 in Q1 2017.
- Funds reported $7.11M of Cellular Biomedicine Group, Inc. stock for Q2 2017, down 57% quarter-over-quarter.
- 8 funds opened new Cellular Biomedicine Group, Inc. positions in Q2 2017 and 18 closed out, a net change of -10 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q2 2017 was Millennium Management, an estimated $1.36M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q2 2017 was BlackRock, an estimated $4.5M sold.
Based on aggregated 13F filings for Q2 2017.